Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-27

Clinical Trial Update: A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings [Phase 4]

View source ↗

Summary

Phase 4 study evaluating paliperidone palmitate for schizophrenia in Rwanda has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INVEGA SUSTENNA (PALIPERIDONE PALMITATE)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED